he initial descriptions of glucose transporter type 1 deficiency (G1D; the result of mutations in the solute carrier family 2 [facilitated glucose transporter], member 1 gene [OMIM 138140]) emphasized its association with intractable infantile epilepsy responsive to a ketogenic diet. Partial deficiency of the glucose transporter 1 (Glut1) protein results in a restriction to the facilitated movement of glucose across brain capillary endothelial and glial cells. 1 This restriction leads to a cerebral carbon (acetyl coenzyme A) deficit, 2 which is at least partially amenable to therapeutic compensation by other sources of carbon. 3 However, G1D affects all ages. In adults, G1D is increasingly recognized and manifests as a mild chronic encephalopathy with infrequent seizures and various degrees of spasticity and ataxia, which is heritable in an autosomal dominant fashion with variable penetrance, or as a residual severe epileptic encephalopathy with onset in early infancy that tends to ameliorate as postpuberal years progress. The former, milder cases frequently remain underdiagnosed and are often detected after the identification of more severely affected offspring. The latter, more severe adult cases are also at risk of missed diagnoses because of a lack of familiarity with the disorder or the limited application of genetic testing. Many patients diagnosed in the past 25 years with G1D are now reaching adulthood.
Although G1D is still considered to be a rare disorder, estimates suggest that it accounts for approximately 1% of idio-pathic generalized epilepsies 4 and approximately 10% of earlyonset absence epilepsies. 5 On the basis of these estimates and the fact that milder phenotypes that consist of less severe symptoms are often not subject to genotyping, G1D is believed to be more common than current prevalence rates would indicate. 6, 7 Cerebrospinal fluid glucose levels are not always determined and may even be normal, limiting their diagnostic reliability. Thus, G1D diagnosis is likely to be dominated by ascertainment biases that result from phenotypic identification. 1 However, a variety of targeted, next-generation DNA sequencing approaches have resulted in the increased detection of G1D in individuals who have never received a lumbar puncture and in adults to whom diagnostic epilepsy DNA panels are applied. Subtypes of the disorder are also best classified by phenotype. The most common phenotype currently known consists of infantile-onset seizures primarily of the absence type, acquired microcephaly, spasticity, ataxia, and abnormal neuropsychological development. 8, 9 Another common phenotype is characterized by motor and intellectual dysfunction without seizures. 10 Seizures associated with G1D are medication refractory, although findings regarding which antiepileptic medications are beneficial, ineffective, or detrimental have been limited and are often contradictory.
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We set out to clarify challenges surrounding G1D diagnosis and treatment through the creation of a patient registry. The registry, the first of its kind to collect detailed medical and treatment history from a broad range of patients diagnosed with G1D, presents an opportunity to explore phenotypes, treatment history, and genotypes.
Methods
The G1D Registry (https://www.g1dregistry.org) is a selfassessment, voluntary, dynamic questionnaire available to patients worldwide. The registry is securely housed within the Health Insurance Portability and Accountability Act-compliant University of Texas Southwestern Medical Center medical records computer servers. The registry was approved by the University of Texas Southwestern Medical Center Institutional Review Board.
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Recruitment methods for the registry included websites (Rare Brain Disorders Program at University of Texas Southwestern Medical Center, clinicaltrials.gov), direct referral from the authors (J.M.P.) at a clinic visit, and links provided in the newsletters from the Glut1 Deficiency Foundation. Study participants provided written informed consent and were allowed to create a username and password for updates to their data. All data were deidentified. The registry questionnaire covered the following areas: (1) diagnosis, including results of any diagnostic tests that patients have completed (such as genotyping); (2) symptoms; (3) symptom history, including medications used; (4) family history; (5) test results (such as blood and spinal fluid tests and electroencephalography, and imaging examinations, including magnetic resonance imaging [MRI] , computed tomography, and positron emission tomography); and (6) medical care, including age when symptoms began, when the diagnostic process began, and when a diagnosis was made. The questions were designed to be easily understood, and all technical terms were defined within the registry. We present findings derived from the first 3 years of the registry (December 1, 2013, through December 1, 2016 Findings In this study of 181 patients with glucose transporter type 1 deficiency in an electronic registry, most patients underwent genetic analysis, with one-fourth of them exhibiting white matter abnormalities by magnetic resonance imaging. Anticonvulsant treatment was ineffective or detrimental, but modified diets were efficacious in two-thirds of cases, with the most important factor in terms of outcome being age at diagnosis.
Meaning
The results of this study indicate a departure from canonical ketogenic diets, emphasize the need for new pharmacologic agents for diet-unresponsive patients, and highlight the value of early diagnosis followed by initiation of dietary therapy.
[63.9%]), and ataxia (87 of 155 [56.1%]). eTable 3 in the Supplement shows the frequency of these manifestations.
Patients reported 3 predominant types of epilepsy. Table 1 lists these types of epilepsy and the patient numbers for each type. Table 2 lists the overlap among these 3 types of epilepsy. The salient neurologic features of the disorder were investigated in terms of patient distribution relative to the persistence of each manifestation (permanent, reversible, or intermittent) under each category (eTable 3 in the Supplement), and manifestations reversible as the result of treatment initiation are noted.
We used the χ 2 test to determine whether there was an association between age group at diagnosis and treatment efficacy. We found P = .02, which was less than the significance level of α = .05, indicating a statistically significant association ( Figure) . We divided the patients into 3 groups according to their ages at treatment initiation: 0 through 2 years, 3 through 5 years, and 6 years or older. Sample rates of full efficacy for the 3 age groups at diagnosis were 93.8% (size 16) for those 0 years old, 52.6% (size 19) for those 1 through 3 years old, and 54.5% (size 11) for those 4 years or older. The association between the age group and efficacy was moderately significant (P =.07 ,χ 2 test) when a significance level of α = .10 was selected. Sample rates of full efficacy were 81.3% (size 16) for those 0 through 2 years old at treatment initiation and 55.6% (size 27) for those 3 years or older group. We next investigated dietary treatment. Table 3 presents the distribution of patients under 3 categories of the dietary treatment: ketogenic diet (with a further subdivision by ketogenic diet ratio), modified Atkins diet, and other special diets, including the low glycemic index diet and its variants.
Benzodiazepines and barbiturates are often, but not universally, contraindicated on the basis of in vitro evidence. 16 We thus asked about treatment-related adverse effects. eTable 4 in the Supplement lists the adverse effects (increased seizure frequency) of the relevant drugs as reported by patients. There was a relatively high incidence of adverse effects for some of these drugs in some of the patients. We analyzed the possible interdependence of treatment efficacy (full, partial) on 3 predictor variables: ketogenic diet ratio, age at diagnosis, and type of (genetic) diagnosis. We used a logistic regression model to predict log odds of full efficacy at a given level of 3 dependent variables. In the first logistic model with 3 predictors, the coefficients for the 2 indicators for type of diagnosis were not significant (P = .97 [estimate = −0.0356, SD = 1.02, z value = −0.035] and P = .94 [estimate = −0.0639, SD = 0.924, z value = −0.069]), and the variable for type of diagnosis could be dropped from the model. We then considered a logistic regression of treatment efficacy depending on ketogenic diet ratio and age at diagnosis variables. This model was significant (P = .02, goodness-offit test, likelihood ratio χ 2 test). We thus concluded that the association between age at diagnosis and treatment efficacy was significant; therefore, we reasonably believe that treatment initiation at a younger age likely yields higher efficacy. As further described below, this logistic model is an apt tool to predict treatment efficacy. Full treatment efficacy was found in 15 patients aged 0 years, 10 patients aged 1 through 3 years, and 6 patients aged 4 years or older. Partial treatment efficacy was found in 1 patient aged 0 years, 9 patients aged Sample rates of full efficacy were 93.8% (size 16) for those 0 years of age, 52.6% (size 19) for those 1 through 3 years of age, and 54.5% (size 11) for those 4 years or older (P =.02,χ 2 test). . We thus conclude that the association between age at diagnosis and treatment efficacy is significant (Figure) . We next asked whether age at diagnosis affects established (later) disease manifestations. We divided the manifestations into 4 types: developmental, neurologic, psychiatric, and others. eTable 5 in the Supplement lists the frequencies of types of manifestations by age group according to their ages at diagnosis. We used a χ 2 test to conduct hypothesis testing.
The association between age group and manifestation type was not significant (93.8% vs 52.6% full efficacy rates for the 0-year age group vs the 1-to 3-year age group, P = .52, χ 2 test).
We also investigated whether the type of genetic mutation affected treatment (diet) efficacy. We divided patients into 3 types according to their DNA genetic diagnoses: deletion or duplication, point mutation, and other types of mutation. eTable 6 in the Supplement gives the frequencies of efficacy under each type of genetic diagnosis by patient count. The association between type of genetic diagnosis and efficacy was not significant (28 with full efficacy and 15 with partial efficacy, P = .35, χ 2 test).
After treatment with the ketogenic diet or the modified Atkins diet, the proportion of patients who still experienced incomplete efficacy was significant, reaching a mean (SD) of 31%(7%)(P < .001).
We next investigated potential associations between manifestations. For a patient with seizures, the most likely associated manifestations were abnormal neurologic development Last, we analyzed treatment efficacy by considering the age at diagnosis and other potentially relevant variables. Specifically, we analyzed whether treatment efficacy (including any treatment) was a function of one or more of the following: age at onset, age at diagnosis, type of diagnosis, and/or treatment modality. We thus studied the dependency of treatment efficacy (full, partial) on 3 predictor variables: ketogenic diet ratio (2:1-5:1), age at diagnosis (0-15 years), and type of (genetic) diagnosis (deletion or duplication, point mutation, or other mutations). We used a logistic regression model to predict the log odds of full efficacy at a given level of the 3 dependent variables. In the model, the diet ratio takes a value from 2 to 5. Ages at diagnosis were divided into 3 groups (representing 0, 1-3, or ≥4 years). Age at diagnosis and type of diagnosis could be represented by 2 indicator variables in the model. We used R statistical software to fit the data for logistic models. In the first logistic model with 3 predictors, the coefficients for the 2 indicators for type of diagnosis were not significant (P = .97 [estimate = −0.0356, SD = 1.02, z value = −0.035] and P = .94 [estimate=−0.0639,SD=0. 924,z value = −0.069]), such that the type of diagnosis could be dropped from the model.
We then considered a logistic regression of treatment efficacy depending on diet ratio and age at diagnosis variables. The model was significant (P = .02, goodness-of-fit test, likelihood ratio χ 2 test). Both ketogenic diet ratio (P = .06) and age at diagnosis (P = .06) were moderately significant for the logistic regression model:
where πi is the probability of full efficacy for each patient, x1 is ketogenic diet ratio, x21 is the first indicator (group 2 if x21 = 1 and x22 = 0) for age at diagnosis, and x22 is the other indicator Other diets 10 (13.0) (group 3 if x21 = 0 and x22 = 1). We conclude that ketogenic diet ratio and age at diagnosis affect treatment efficacy. In the fitted logistic regression, the intercept is 5.9967 (95% CI, 1.3552-10.6382; P = .01, Wald test), the coefficient for ketogenic diet ratio is −1.1979 (95% CI, −2.4476 to 0.0518; P = .06), the coefficient for age group 2 is −2.4365 (95% CI, −4.441 to −0.4322; P = .02, Wald test), and the coefficient for age group 3 is −1.2768 (95% CI, −3.3027 to 0.7491; P = .22, Wald test). Age group 1 at diagnosis and age group 2 affected treatment efficacy significantly (P = .02), whereas age group 1 at diagnosis and age group 3 did not have any significantly different effect on efficacy (P = .21). All 3 coefficients were negative, indicating that a greater ketogenic diet ratio and a younger age at diagnosis increase efficacy (ie, the probability of full efficacy). Thus, the model can be used to predict the probability of full efficacy. For example, at a ketogenic diet ratio of 2.5:1 and an age at diagnosis of 3 years (group 2), the model predicts that the odds are 1.76, and therefore the probability of full efficacy is 0.6377.
Discussion
The data from this global registry strongly suggest that there should be a reassessment of G1D syndrome despite the limitation that participants were not examined in a clinic setting. In this 181-patient registry, most patients underwent genetic analysis, with one-fourth of them exhibiting white matter abnormalities by MRI. Anticonvulsant treatment was ineffective or detrimental, but modified diets, such as the modified Atkins diet or the low glycemic index diet, were efficacious in two-thirds of cases. This rate of efficacy resembles that of the canonical ketogenic diet. Adherence with these diets may lead to a better outcome. The most important prognostic determinant in terms of outcome was age at diagnosis. In summary, these results indicate a departure from canonical therapeutic ketogenic diets, emphasize the need for new pharmacologic agents for dietunresponsive patients, and highlight the value of early diagnosis followed by initiation of a dietary therapy. Of note, it is possible to predict long-term clinical outcomes using our regression model and age of diagnosis as the dominant variable. This finding suggests that the age at treatment initiation is more important than the type of dietary treatment followed thereafter.
Manifestations of G1D
The registry data allow for a relatively sharp definition of G1D syndrome; G1D has no obvious sex or racial predilection. Most cases are diagnosed in early infancy, a phenomenon that may have prognostic implications. Most patients (69.7%) experience abnormal intellectual development. Seizures follow in frequency. These seizures are most often convulsive and generalized, followed by absence seizures coexisting with generalized convulsive seizures. Ataxia is also common (56.1% of cases). A variety of nonspecific MRI abnormalities are found in as many as one-fourth of cases. Episodes of full-body weakness and intermittent involuntary gaze affect one-fourth of cases. In approximately half of patients, seizures prove to be a transitory phenomenon that subsides with therapy. The other half continues to experience appreciable seizures (however, less frequently) despite treatment. This finding is unexpected within the paradigm that considers the ketogenic diet an effective substitutive intervention. In addition to seizures, recurrent features that may be refractory to treatment include ataxia, alternating hemiplegia, dyskinesia, and episodic generalized weakness. Psychiatric manifestations (predominantly obsessivecompulsive trait) appear in childhood and persist.
Diagnostic Methods
The diagnosis of G1D is primarily based on genotyping. Other alternative methods, such as the determination of cerebrospinal fluid glucose concentrations, are prone to uncertainty and have become less frequently used. Approximately 8% of all patients have been diagnosed on the basis of positron emission tomography findings, 17 although the sensitivity and specificity of this technique remain unknown. Red cell assays for glucose transport are subject to variability and are thus not generally used.
Effect of Early Diagnosis
The most important factor for predictive outcome is age at diagnosis, which corroborates sequential observations made in a series of 133 patients. 18 Neither the type of genetic mutation nor the ketogenic diet ratio (when treated with a ketogenic diet) exert any strong effect on phenotype or response to therapy, with ketogenic diet ratio having only a modest effect on treatment outcome. This finding militates against any genotypephenotype correlations. 19 It also argues against recommendations for higher-ratio ketogenic diets, especially when these high ratios are not well tolerated.
Treatments
Most patients receive a ketogenic diet at a 3:1 ratio. However, a significant fraction receive a modified Atkins diet or a low glycemic index diet and its variants. This finding is consistent with a survey of 92 patients receiving dietary therapies. 20 However, diet effectiveness decreases when initiated throughout late childhood. Several anticonvulsants have been discouraged on the basis of in vitro experimental concerns related to direct inhibition of the Glut1 transporter. Among these, benzodiazepines and barbiturates are often used in infantile epilepsies. Consistent with the recommendations to refrain from using benzodiazepines, these agents were, as a group, associated with aggravation of seizures in a relatively disproportionate number of patients, although our data are preliminary in this regard.
Outcome
Our regression model allows for a general prognostic estimation using the age at diagnosis as the principal relevant variable, which holds true especially when diagnosis is followed by any form of tolerable dietary treatment. Mutation type and ketogenic diet ratio are subordinate to age at diagnosis, highlighting the relevance of early diagnosis and therapy.
Limitations
Our analysis is limited by the fact that patients were not available for interview and that the data were not independently corroborated. 24  33  33  19  22  7  10  11  14  2  5 The age refers to the time of initial registration.
